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Summary 
While human genetic modification has long been the subject of bioethical 
attention, the advent of new ‘genome editing’ techniques such as the CRISPR/Cas 
system has provoked renewed interest in this area.  The comparative efficiency 
and precision of these techniques greatly increases their value to research as 
well as the scope of possible applications.  Genome editing, in combination with 
stem cell science, has the potential to produce a new generation of somatic gene 
therapies. It is perhaps, however, the fact that these techniques make 
reproductive germline genetic modification a real and practicable possibility that 
has sparked scientific and ethical attention. 
While a moratorium on genome editing research, such as that called for by some 
in the wake of the first reported use of CRISPR in human embryos, may not be an 
effective or justified solution to such concerns, questions remain as to how such 
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technologies should be regulated. A significant issue is that the attention given to 
genome editing techniques and their therapeutic potential is likely to stimulate 
demand from patient groups, especially in the case of conditions for which there 
are currently no effective treatments – as has happened with stem cell therapies.  
This, together with the relative ease of application of genome editing techniques, 
creates the very real possibility that (as for stem cells) in the absence of 
adequate regulation or oversight, clinical treatments using genome editing, 
whether somatic or reproductive, may be offered ahead of sufficient testing of 
safety and efficacy.  This is likely to be most problematic in countries where 
unlicensed therapies are already prevalent; Mexico, for example, is a known 
destination for stem cell ‘treatments’, at least some of which are offered without 
rigorous scientific validation. Moreover, the phenomenon of medical tourism 
means that this is not just a problem for these countries but one that requires 
global cooperation to achieve an effective transnational regulatory solution. 
In this paper we consider the ethical and regulatory challenges presented by 
genome editing technologies and the problem of ‘rogue’ therapies, using the 
Mexican context as a case study to illustrate the potential pitfalls and issues that 
will need to be addressed to achieve effective governance in this area.  Drawing 
on lessons learned from other areas of science and other jurisdictions, we 
suggest some principles that may help to develop an appropriate framework for 
regulating this fast-moving area of science. 
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1. INTRODUCTION 
1.1 The ethics of genetic modification: 40 years of debate 
Genetic modification first seriously came to public attention in the early days of 
recombinant DNA.  The Asilomar conference in 1975, convened in response to 
growing public and scientific concerns over the use of recombinant DNA 
technology, was seen as a landmark that brought genetic engineering into the 
spotlight even as it secured scientists’ license to carry on developing this 
work[1–3].  Yet although Asilomar enabled the blossoming of molecular genetics 
that has since had a transformative effect on biology and biotechnology, ethical 
and social concerns, particularly regarding the prospect of human genetic 
engineering, continued to provoke ongoing debate. 
Fast forward 40 years and the big picture looks surprisingly similar: genetic 
engineering is seldom out of the headlines, and human genetic modification 
remains the subject of passionate debate.  Genetic modification is by now a 
familiar topic for bioethics, but its current prominence is the result of a new 
wave of technologies known as ‘gene editing’ or ‘genome editing’, that has 
provoked renewed interest in these issues, and human germline genetic 
modification (HGGM) in particular. 
The theoretical issues surrounding HGGM are not new; they have been explored 
extensively elsewhere[4–8] and we will not review them here.  Our aim in this 
paper is to address the ethical and regulatory issues that we see as of most 
current importance in relation to genome editing, both as a research tool and for 
potential clinical application.  Although the most appropriate regulatory 
distinction would seem to be between research and clinical application, research 
that seems to be directed at achieving eventual HGGM applications has been seen 
as a special case; we suggest, however, that there are insufficient grounds to rule 
out such research while the ethical debate remains unresolved.  In relation to 
possible applications, of most concern is the potential for treatments based on 
gene editing techniques to be offered prematurely and to find ready customers 
on the international health market, ahead of adequate tests to determine safety 
and efficacy.  We suggest that global cooperation across a number of spheres of 
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regulation, not only gene editing itself, is required to address this issue. 
 
1.2 Genome editing: same goals, new methods 
Foremost among the new generation of what are being called ‘gene editing’ or 
‘genome editing’ technologies is the CRISPR/Cas system[9] (henceforth referred 
to as CRISPR), which uses a guide RNA together with a nuclease enzyme that cuts 
the DNA to achieve specific targeted modification of the desired sequence.  Other 
tools such as ZFNs[10] and TALENs use DNA-binding proteins for the targeting 
step, but the principle is similar. 
The main factor that has transformed the scientific landscape and hence the 
issues of ethical concern in practice is the ease of use and efficiency that gene 
editing technologies represent.  Previous methods available for targeted genetic 
modification had a much lower efficiency.  This meant that to create genetically 
modified mammals, such as mice, the gene targeting step had to be done in cells 
in vitro, to allow the few cells out of thousands that might bear the desired 
modification to be selected; these cell lines could then be inserted into embryos 
to produce ‘chimeric’ organisms that would carry the modification in some of 
their cells, and breeding and back-crossing the chimeras would produce 
subsequent generations all carrying the modified gene. 
This process of genetic modification has been used successfully for years to 
create transgenic mice, providing valuable research tools[11]; it was clearly 
unacceptable, however, for use in humans.  The impracticalities of carrying out 
HGGM using these techniques meant that bioethicists could ‘agree to disagree’: 
that whether they opposed or accepted the possibility of HGGM in principle, all 
could agree that the methodological and safety obstacles were such that it ought 
not to be attempted in practice. 
By contrast, the high efficiency of CRISPR means that the method can be applied 
directly to an embryo to create the genetic modification in some or all of that 
embryo’s cells; if the embryo is allowed to develop, the resulting human being 
would then carry that modification.  He or she would not be a ‘chimera’ (with 
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cells from two distinct origins), though might be a ‘mosaic’ (where cells of the 
same organism differ genetically), if the CRISPR modification does not take effect 
identically in all cells of the embryo.  The new technique removes many of the 
obstacles of the previous method and, together with advances in other areas 
such as whole-genome sequencing and assisted reproductive technologies, 
suddenly makes HGGM a much more feasible prospect. 
 
2. ETHICAL ISSUES 
2.1 CRISPR and human germline genetic modification 
While the CRISPR method was published in 2012, public interest and concern 
over the technique surged in 2015, when in April a paper reported the use of 
CRISPR to modify human embryos[12].  Around the same time, two groups of 
scientists published commentaries, in Science[13] and Nature[14] respectively, 
each calling for restrictions on particular uses of gene editing technology in 
relation to human embryos.  One group advocated for a voluntary moratorium 
on all gene editing of embryos, saying that “scientists should agree not to modify 
the DNA of human reproductive cells”, for fear that other forms of gene editing 
research would be ‘tarred with the same brush’, impeding valuable science[14]. 
The second was more moderate, focusing on specifically on clinical reproductive 
use and calling for measures to “[s]trongly discourage, even in those countries 
with lax jurisdictions where it might be permitted, any attempts at germline 
genome modification for clinical application in humans”[13].  They were united, 
however, in identifying the use of gene editing to create children as 
impermissible at the present time. 
One question that arose in relation to the use of gene editing in embryos was 
whether this actually constituted HGGM in the sense to which most ethical 
concerns attach, that is, modifying the genome in a way that will be heritable and 
affect future generations.  These were the fears suggested by the plea of one of 
the above-mentioned groups, Lanphier and colleagues – “Don't edit the human 
germline”[14].  As well as their worries about public perceptions of HGGM 
getting in the way of other uses of gene editing, they cited concerns over the 
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eventual prospect of “non-therapeutic genetic enhancement” as a reason to 
oppose any form of germline genetic modification, including embryo research. 
According to the scientific definition, the germline includes germ cells and any 
cell that could give rise to them.  This could be seen to include not only gametes 
and pluripotent cells of the early embryo but, given the capacity to produce 
gametes in vitro from induced pluripotent stem cells, potentially any somatic cell 
– a broad definition indeed. 
What we are really concerned about in ethical discussions of ‘germline genetic 
modification’, however, is the creation of genetically modified human beings – 
not whether some cell in a dish that could potentially one day become or give 
rise to a cell that might contribute to becoming a human being is modified, but 
whether that potential is ever actualised. 
In the case of the first paper that reignited the controversy, the embryos used in 
fact had no potential ever to become persons, as they were incapable of 
developing beyond a relatively early stage.  Comments by the authors indicated 
that non-viable embryos had been chosen in order to address ethical concerns 
about germline genetic modification[15]. (The research was in fact criticised 
scientifically on those grounds, since the abnormality of the embryos used might 
limit the usefulness of the results for understanding gene editing in normal 
embryos.) 
But even a viable embryo will not develop into a human being unless implanted.  
If what we are concerned about is the production of genetically modified 
children, what is important is not whether human embryos are modified, but 
whether those embryos are ever destined to become children and whether we 
enable them to do so by implanting them.  Hence, many argued, the distinction 
ought to be drawn between research versus reproductive uses, rather than 
between somatic and germline modification. 
This distinction, and the fact that gene editing could still lead to much valuable 
research not aimed at reproductive uses, was one that responses aimed at policy 
were most concerned to emphasise.  The various statements produced by UK 
bioscience funders[16], the Hinxton Group[17,18] and the National Academies 
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international summit meeting in December 2015[19] all stressed the importance 
of basic gene editing research and that this should not be impeded by concerns 
over application. 
 
2.2 Steps towards HGGM: the slippery slope revisited? 
Nevertheless, the prospect of ongoing research with gene editing in embryos, 
including reports of the first such experiments licensed by the UK’s national 
regulator, the Human Fertilisation and Embryology Authority[20], has continued 
to fuel debate.  Further ‘slippery slope’ concerns were provoked by the recent 
publication of a study reporting attempts in human embryos to edit a gene that 
could confer HIV resistance[21]. 
The slippery slope concern in its wide form often attaches to an entire range of 
basic research that (in the case of gene editing) could eventually contribute to 
producing a genetically modified human but could also be used for many other 
valuable purposes, rendering this objection irrelevantly broad.  This particular 
objection, however, sheds a somewhat different light on the slippery slope 
problem.  The two-dimensional ethical slope, with a seemingly innocuous step at 
the top and an inevitable slide down to moral bankruptcy at the bottom, is not a 
very good metaphor for the reality of how science develops.  Science, with its 
myriad possibilities, is more like a rubber-sheet representation of the topology 
of the universe, with three-dimensional bumps and dips: from any given point, 
we can roll in many different directions, only some of which might or ought to 
cause concern. 
In this case, the HIV-resistance research was seen as ‘rolling’ in an alarming 
direction, where other forms of embryo research were not.  Commentators 
perceived a distinction between different kinds of embryo research: basic 
research “answering questions intrinsic to embryology”[21] was deemed 
acceptable, whereas this was seen as a step directly towards human germline 
genetic modification.  The Hinxton Group Statement also recognised “research to 
inform the plausibility of developing safe human reproductive 
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applications”[17,18] as a distinct category, though did not explicitly comment on 
its acceptability as such. 
The ethical question this raises bears considering, given that embryo gene 
editing, including research that might pave the way towards HGGM, is likely to 
increase in the near future: If we consider it is, or it might be wrong to do X, is it 
wrong to do steps A, B and C that can lead to X? 
One response might be that A, B and C don’t have to lead inevitably to X: 
although X might require us to first do ABC, doing ABC does not require that we 
must then do X.  If steps ABC don’t obviously lead anywhere else useful, however, 
there would seem to be little point in doing them other than to lead to X.  If we 
have already decided that we should not do X, then this allows us to contend that 
we ought not to do ABC on the grounds that it represents a waste of resources 
and effort; that there are better things to do all things considered; and that the 
goals of science would be better served and resources better used by pursuing 
other forms of research.  The argument gains further strength when the research 
in question involves human embryos: as these are a limited and valuable 
resource invoking moral sensitivities, it is seen as particularly unjustified to use 
them for pointless or frivolous experiments – “just playing with human 
embryos”[22]. 
This line of argument holds, however, only in the case where we have concluded 
that X would be wrong.  With respect to HGGM, it is not clear that this is the case.  
Scientists and ethicists agree that using gene editing to create GM humans now 
would be wrong, whether simply premature for reasons of safety or because 
creating a GM human is intrinsically wrong.  It is by no means universally agreed, 
however, that it will always be wrong: the bioethical jury is still out, with strong 
advocates on both sides.  The most we can say, with respect to HGGM, is that we 
have not yet resolved the question of whether it is right or wrong to do X.  Indeed 
some lines of argument hold that it would be wrong not to do it, that if HGGM will 
lead to benefits such as improving human welfare, we have a moral obligation to 
pursue it.  In this situation, it is far from clear that it is wrong to do steps ABC 
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Thus, although some described the HIV-resistance experiment as “the science… 
going forward before there’s been the general consensus after deliberation that 
such an approach is medically warranted”[22], the science would seem to be a 
necessary part of determining whether this approach is medically warranted; 
what we have not yet determined is whether it is ethically warranted, but while 
the ethical issues remain in question, scientific investigation to answer the 
scientific questions is not unjustified. 
 
2.3 A market for gene therapies 
Many more questions remain to be answered in determining whether and how 
we as a society should proceed towards eventually using gene editing to create 
genetically modified human beings.  We suggest, however, that the biggest 
concern in relation to gene editing at the present time is not the possibility of 
eventual HGGM and whether we should be taking small steps towards it as part 
of a scientifically well-defined process that would adequately characterise the 
technical risks at the same time as engaging in appropriate social discourse over 
the ethical concerns.  The greater worry is that there may be those who, seeing a 
market opportunity, are willing to take great leaps (or at least claim that they 
are) and start offering products or treatments based on (or under the banner of) 
gene editing. 
That such a market opportunity exists, and those willing to take advantage of it, 
is aptly demonstrated by that other exemplar of ethically contested 
biotechnology: stem cell science.  While ethical debate over stem cells has 
focused more on research than on application (the main issue of course being 
around the destructive use of human embryos in generating embryonic stem cell 
lines), it is another area which holds great therapeutic promise that is, however, 
still largely in the developmental phase.  Of course some forms of stem cell 
therapy, notably haematopoietic cell therapy in the form of bone marrow 
transplantation, have been in use for many years; but other cell therapies, 
including interventions using both embryonic and tissue-derived stem cells, are 
still at an early stage.  Despite this, however, there has been a proliferation of 
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clinics offering treatments that they claim are based on these still-unproven 
techniques[23,24].  Often these clinics advertise direct to consumers, offering 
generic treatments for an improbably wide range of conditions, based on 
anecdote and testimony rather than scientific evidence, without any apparent 
intention to collect data on their further use in order to contribute to a scientific 
evidence base, and at considerable cost to patients[25,26]. 
This phenomenon is a widely recognised one, and of great concern to scientists 
and ethicists alike[27–29].  Not only does it illustrate the possibility for the same 
to occur with gene editing but, because somatic gene therapy will also require 
stem cell technology, an easy opportunity exists for the same operators to 
branch out and add gene editing to their catalogue.  Moreover, attempts at 
reproductive germline editing would also be possible: “the ease of use and 
accessibility of the technology make it ripe for exploitation by rogue or charlatan 
organizations, especially in jurisdictions where fertility clinics… are loosely 
regulated”[30]. 
To be clear, the concern here is not that rogue operators offering insufficiently-
tested gene editing treatments will bring about some unmitigated population-
wide disaster to the human genome at large. Most likely, as with some of the 
‘stem cell treatments’ currently on offer, they will not work at all, or if they work 
in ways so as to have effects other than expected, these will be limited to the 
patient themselves. 
Of course the negative consequences for patients themselves are something we 
should be concerned to avoid, both the exploitation and waste of resources that 
occurs when patients are induced to spend their money (and as in the case of 
stem cell interventions, these procedures are likely to carry a high price tag) and 
invest hope and effort into bogus treatments as well as the potential for direct 
harm caused by insufficiently-tested interventions. 
But the possibility of gene editing ‘treatments’ being offered ahead of adequate 
scientific validation may also have more far-reaching harmful consequences.  
The provision of interventions that are ineffective or downright dangerous is 
liable to result in a loss of faith in science, damage the relationship of trust 
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between science and publics more generally, and diminish support and 
resources available for research of actual value. 
All of these concerns are present with respect to stem cells[31] and will be no 
less so if gene editing becomes the next source of quackery, or if some ‘maverick’ 
proves willing to take the most controversial step of using gene editing to create 
a genetically modified child. While the scientific community in general has been 
strongly opposed to clinical reproductive uses of gene editing, this does not 
guarantee that no individual will take this step: some have apparently been 
willing to make – and report – attempts at that other almost-universally-
condemned procedure, human reproductive cloning[32]. 
Above all, therefore, the ethical, practical and regulatory challenge of gene 
editing that we need to address is: how we can take steps to prevent ‘quack’ 
treatments supposedly based on gene editing from becoming established, how 
we can avoid as much as possible premature applications of this technology, and 
how to manage the social consequences if (or perhaps when) this does occur.  
Furthermore, the transnational market for new health technologies, created by 
ready access to online information together with medical tourism, makes the 
global approach that has been called for even more crucial. 
Mexico provides an example of how these factors combine to permit the growth 
of such a market: it and other countries have emerged as potential destinations 
for patients to obtain ready access to non-proven applications. This has been 
identified as a key concern in stem cell science[33], with scientists advocating for 
regulation in order to promote responsibility and prevent the marketing of 
premature, unproven and potentially harmful interventions in the guise of 
science[34]. The field of gene editing, as noted, has similarities that if 
unaddressed may see it go down the same route.   
In the third part of this paper, therefore, we move onto considering the prospects 
and priorities for regulating the use of gene editing technologies.  We take the 
example of Mexico to illustrate some of the issues that will arise, nationally and 
internationally, as gene editing research moves forward and its potential 
applications develop. 
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3. Regulating controversial research: the case of Mexico 
The Mexican situation provides an illustration of the consequences of inadequate 
regulation, while also demonstrating the complex factors – scientific, regulatory, 
economic and social – that intersect to shape the terrain of science and new 
health technologies in practice.  In this section we examine the Mexican 
regulatory landscape with respect to biotechnology and its implications for gene 
editing technologies, both in research and clinical application, and identify 
challenges that must be addressed. 
3.1 Regulation of biotechnology and gene editing in Mexico 
Regulatory attention to genetic technologies in Mexico has largely concentrated 
on genetically modified organisms (GMOs), with a particular focus on biosafety 
and agriculture.  The Inter-Ministerial Commission For Safety of Genetically 
Modified Organisms (CIBIOGEM) was formed in 2000 to coordinate biosafety 
policy and oversee all aspects of the production, import, export and use of 
GMOs[35].  These functions were formalised in 2005 by the Law on Biosafety of 
Genetically Modified Organisms[36], which was created in order to manage 
potential risks associated with GMOs and promote the ethical development of 
this area of biotechnology.   
The development of these regulations was influenced by a host of intersecting 
factors and conflicting interests, particularly related to the Mexican and multi-
national biotechnology industry; international trade and economic interests; 
compliance with international governance; food security; and environmental and 
biosafety concerns.  High on the agenda was the issue of maize, part of Mexico’s 
cultural gastronomic heritage as well as a staple food crop for the region and a 
major foreign import[35,37]. The Law on Biosafety has itself been criticised as an 
“essentially symbolic” response to these competing concerns[37], and while we 
have focused in this paper on human research and applications, it is worth 
noting that the potential impact of gene editing with respect to agriculture and 
the environment is likely to propagate and perhaps exacerbate such conflicts. 
Significantly, the Law on Biosafety specifically disclaims responsibility for 
regulating human genetic modification by stipulating that ‘human beings’ are not 
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considered ‘organisms’ for the purposes of the law[36 Article 3(XX)] and 
excluding from its jurisdiction the human genome, stem cell culture and the 
modification of human germ cells, stating these to be the province of the General 
Health Act[38] (GHA) and international treaties[36 Article 6(V)].  As we shall see, 
however, the GHA and its application, and the other laws that make up the 
Mexican regulatory landscape, nevertheless leave considerable uncertainty in 
this area. 
While the GHA contains a section on ‘The Human Genome’[38 Título Quinto Bis], 
this mainly concerns the uses of genetic information; genetic modification is not 
explicitly dealt with.  As for the regulation of research on human embryos, 
gametes and stem cells, this has long been a contested area in Mexico[39]; while 
the GHA and its associated regulations contain various provisions that might be 
interpreted to apply, they are very broadly framed, and hence the national 
regulatory framework remains unclear[40].   
At a state level, Mexico City’s criminal code[41] contains a few relevant 
provisions: it proscribes the use of donated gametes for a different end from that 
established in the donor’s consent[41 Article 149], which would seem to permit 
the use of gametes for scientific research if consent is granted, but fertilisation of 
eggs for any purpose other than reproduction is forbidden[41 Article 154]. This 
precludes the creation of embryos specifically for research, which may be 
important in gene editing work[17,18], but not the use of supernumerary 
embryos.  It prohibits manipulation of human genes “so as to alter the genotype” 
for any purpose other than eliminating or improving disease[41 Article 154(1)], 
but it is not clear what is meant by this.  It forbids any procedure of genetic 
engineering for “illicit ends”[41 Article 154(III)], but fails to describe which kind 
of ends would be licit.  There is thus little in the way of specific regulation to 
govern human gene editing and associated research techniques.   
 
3.2 Regulatory gaps from research to ‘therapy’: lessons from stem cell science 
The legal lacuna in relation to biomedical research and technology presents a 
problem in many ways. It generates uncertainties for scientists working in 
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universities and national healthcare research institutions as to whether certain 
research activities are permitted and to what extent.  It may also encourage 
scientific and medical tourism in order to escape more restrictive laws in other 
jurisdictions and access treatments unavailable under stricter regulations, as has 
been the case with stem cell science[42].  Mexico has emerged as a destination 
for stem cell tourism, leading to the proliferation of unsubstantiated therapies 
being sold by private clinics in the guise of science: for example, the 
Regenerative Medicine Institute of Hospital Angeles in Tijuana advertises and 
markets experimental autologous stem cell treatments as “an alternative to SC 
therapies not yet approved by the US FDA” [43]. 
The Mexican situation also demonstrates that in order to be effective, regulation 
must be sufficiently specific, enforceable and actually enforced.  The GHA and its 
associated regulations explicitly prohibit the commercialisation of human tissues 
and cells and their derivatives[38 Articles 315-327] and provide that any 
therapeutic procedures involving these materials must be gratuitous.  The law 
also stipulates that healthcare providers and establishments must be licensed 
and authorised by the Federal Regulatory Commission for Sanitary Risks 
(COFEPRIS) if they are to administer or conduct experimental medical 
procedures. However, nothing in the law directly addresses the clinical 
application of stem cells or stem cell derived products; the terms of the law are 
vague. 
In practice, experimental therapies are easily available and commercialised all 
over Mexico.  The lack of effectively targeted legislation means that operators 
can escape regulation by switching terms for activities, which also confuses 
potential patients. For example, although commercialisation of tissues and cells 
themselves is not permitted, operators instead charge for the costs of the 
procedure, isolation, processing and so on, with the effect in practice of creating 
a thriving commercial market.  This leaves patients exposed to physical and 
financial burdens and risks when undertaking unregulated stem cell-based 
therapies, which are widely available. Moreover, the regulatory agency has failed 
to effectively monitor, supervise and sanction healthcare providers and 
purveyors of dubious treatments[43]. The ineffective enforcement of the law is 
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partially explained by the current regulatory authorities lacking compliance 
mechanisms and the resources, both human and financial, to pursue them, 
making it difficult to apply existing legal provisions, a situation not helped by the 
lack of more targeted legislation.  
Notwithstanding the legal lacuna with respect to stem cells as such, the relevant 
law explicitly prohibits the profit-seeking utilisation of tissues and cells. The 
governance of innovative applications is a “delicate balancing act between 
minimizing overregulation while still assuring adequate protection of research 
subjects”[44]. The current laissez-faire regime in Mexico, however, has allowed 
the spread of experimental stem cell treatments, putting at risk patients’ 
wellbeing and giving rise to significant ethical and legal issues[43]. 
There are important lessons from this for the regulation of gene editing and 
other forms of biotechnological innovation.  In the concluding section, we apply 
insights from Mexico to suggest considerations for developing regulation for 
gene editing and other technologies. 
 
4. Conclusions: the way forward? 
International regulation of gene editing is something of a patchwork at present 
with respect to different countries and the various aspects of science 
involved[45,46].  In some jurisdictions and areas there is little or no regulation; 
in others, such as Mexico, laws are overly broad or vague, which may make 
effective implementation difficult; some countries have more developed systems 
for regulation across relevant areas.  A key theme that has emerged from 
discussions so far, however, is that international cooperation is required to 
develop and implement appropriate guidelines[17–19].  The need for ongoing 
discourse and more meaningful engagement is also well recognised.  While it is 
likely that gene editing research, especially on human embryos, will remain 
controversial, this should not be permitted to lead to regulatory stalemate. 
This is equally if not more important when it comes to potential clinical 
applications.  Before any therapies become easily available, it is essential that 
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they be adequately verified.  Medical tourism and internet marketing mean that 
the problem of unproven treatments transcends national boundaries, and 
opportunistic providers have shown themselves willing and ready to exploit 
regulatory differences to profit from patients’ desperation.  A concerted 
international approach will be necessary to address this.  Cooperation and 
engagement between and within stakeholder groups is also crucial in order to 
disseminate accurate information in relation to the current status of clinical 
applications, and may help in implementing best practice at other levels, such as 
through professional regulation[47]. 
With respect to both research and therapy, not just the existence of on-paper 
regulation but effective mechanisms for oversight and compliance are necessary: 
regulatory agencies require sufficient power to implement international 
guidelines and standards in this area. This must be combined with adequate 
resources, financial as well as human in the form of trained personnel, to 
monitor the relevant areas of research and health care in order to effectively 
enforce the legislative provisions adopted.  In terms of setting these standards, 
however, it is also important to promote genuine international discourse that is 
sensitive to differences in culture, including the culture of science; simply 
exporting regulatory systems and standards from one region to the rest of the 
world creates the danger that the principles and values of developed countries 
will dominate even when they should not. 
Additionally, while regulation needs to be sufficiently targeted and specific to be 
effective, gene editing and genetic modification cannot be the sole focus of our 
regulatory efforts.  If a major concern is to prevent premature clinical 
reproductive application, then effective oversight of reproductive technologies is 
also necessary and will complement efforts to control reproductive uses of gene 
editing.  Likewise if we are concerned with the provision of somatic gene 
therapies, then regulation of the uses of cells and tissues will be important.  
Finally, we must recognise and confront the influence of economic interests and 
unmet health needs, in shaping the regulation of science and innovation, and in 
creating and sustaining a market for untested, possibly ineffective and/or 
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dangerous treatments based on emerging biotechnologies.  Stringent regulatory 
hurdles may pose a disincentive for biotechnological development, with 
scientists and investors threatening to go elsewhere, while countries with more 
relaxed regulation might be seen as attractive by investors looking for an easy 
opportunity.  Meanwhile, people desperate for cures create a demand for 
treatments that the market is perhaps too ready to supply, resulting in a new 
tension between scientists who warn against unproven applications and patients 
who believe they are being unfairly denied access.  A de-regulated health 
technology market is not the way forward, however, unless we believe profit 
rather than patient welfare to be the ultimate goal of science.   
Attempts to avert the premature application of gene editing in the clinical 
context must thus form part of a more holistic approach to health technology 
markets and medical innovation.  The same forces and factors that are enabling 
the market in unproven ‘stem cell’ treatments to thrive and allowing or even 
promoting the marketing of other interventions ahead of adequate proof of 
safety and efficacy, are those which, if not checked, will allow gene editing to go 
the same way. 
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